AMPYRA® (dalfampridine) is an oral medication that helps
improve walking in patients with Multiple Sclerosis.
I will:
“The first thing I started to
notice as my walking improved with
Ampyra was my confidence in my ability
to walk to meet my friends.”
— Kristie Salerno Kent,
diagnosed with MS in 1999.
Walk on.
Walking better matters. AMPYRA
is the first and only medication
shown in two clinical trials to
improve walking in people with
multiple sclerosis (MS).
This was demonstrated by an
increase in walking speed.
In these clinical studies, people who
walked faster, regardless of treatment,
reported improvements in their
walking related activities.
Not everyone responds to AMPYRA.
Individual results may vary.
Can be taken in combination
with your other MS therapies.
Visit Ampyra.com to find out
more about a FREE* TRIAL.
*Limitations and Restrictions apply.
Talk to your doctor to see if AMPYRA may be right
for you.
IMPORTANT NEW SAFETY INFORMATION
Do not take AMPYRA if you are allergic to
dalfampridine (4-aminopyridine), the active
ingredient in AMPYRA.
IMPORTANT SAFETY INFORMATION
Do not take AMPYRA if you have ever had a seizure,
or have certain types of kidney problems, or are
allergic to dalfampridine (4-aminopyridine), the active
ingredient in AMPYRA.
Take AMPYRA exactly as prescribed by your doctor.
You could have a seizure even if you never had a seizure
before. Your chance of having a seizure is higher if you
take too much AMPYRA or if your kidneys have a mild
decrease of function, which is common after age 50.
Your doctor may do a blood test to check how well your
kidneys are working, if that is not known before you
start taking AMPYRA.
In two pivotal trials 35% and 43% of patients taking
AMPYRA responded to treatment vs. 8% and 9% of
patients taking placebo.
AMPYRA® is a registered trademark of Acorda
Therapeutics®, Inc. AMPYRA is marketed by Acorda
Therapeutics, Inc. and is manufactured under license
from Alkermes Pharma Ireland Ltd. © 2013 Acorda
Therapeutics, Inc. All Rights Reserved. 03/13 AMP2299
AMPYRA should not be taken with other forms of
4-aminopyridine (4-AP, fampridine), since the active
ingredient is the same.
AMPYRA may cause serious allergic reactions. Stop taking
AMPYRA and call your doctor right away or get emergency
medical help if you have shortness of breath or trouble
breathing, swelling of your throat or tongue, or hives.
Please see the full Patient Medication Guide on the
following page.
You are encouraged to report negative side effects
of prescription drugs to the FDA. Visit www.fda.gov/
medwatch, or call 1-800-FDA-1088.
